You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HLA-A2 positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor Trial in Houston (Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide)

Not yet recruiting
  • Solid Tumor
  • Single Injection of IVS-3001- Anti - HLA-G CAR-T cells
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2023

Metastatic Triple-Negative Breast Carcinoma Trial (PVX-410)

Not yet recruiting
  • Metastatic Triple-Negative Breast Carcinoma
  • (no location specified)
Apr 18, 2022

HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

Recruiting
  • HLA-A2 Positive Cells Present
  • Refractory Melanoma
  • Alpha-type-1 Polarized Dendritic Cells
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 12, 2022

Glioblastoma Multiforme of Brain Trial in Tübingen (Multipeptide plus XS15)

Recruiting
  • Glioblastoma Multiforme of Brain
  • Multipeptide plus XS15
  • Tübingen, BW, Germany
    University Hospital Tübingen
May 9, 2022

Ovarian Cancer Trial (Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in

Not yet recruiting
  • Ovarian Cancer
  • Autologous genetically modified ADP-A2M4CD8 cells
  • Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
  • (no location specified)
Jan 31, 2023

Oropharyngeal Squamous Cell Carcinoma Trial in Saint Louis (CUE-101)

Recruiting
  • Oropharyngeal Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 22, 2022

Tumors Trial in Worldwide (Letetresgene autoleucel)

Active, not recruiting
  • Neoplasms
  • Letetresgene autoleucel
  • Pittsburgh, Pennsylvania
  • +5 more
Aug 7, 2023

Triple Negative Breast Cancer Trial in Los Angeles (biological, procedure, drug)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Aldesleukin
  • +12 more
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Aug 9, 2023

Advanced Solid Tumors Trial in Chongqing (TC-N201 cells, IL-2, Fludarabine)

Recruiting
  • Advanced Solid Tumors
  • TC-N201 cells
  • +4 more
  • Chongqing, China
    TCRCure Biopharma Ltd.
May 25, 2023

Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)

Not yet recruiting
  • Solid Tumors
  • TCR-T cells
  • +4 more
  • (no location specified)
Dec 12, 2022

Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified

Recruiting
  • Endometrial Cancer
  • +8 more
  • Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
  • Orlando, Florida
  • +21 more
Feb 2, 2023

Advanced Melanoma Trial (Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice)

Not yet recruiting
  • Advanced Melanoma
  • (no location specified)
Sep 19, 2022

COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)

Active, not recruiting
  • COL6A3 Positive
  • +3 more
  • Aldesleukin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Select Advanced Solid Tumors Trial in Canada, United Kingdom, United States (IMCnyeso)

Terminated
Has Results
  • Select Advanced Solid Tumors
  • Aurora, Colorado
  • +11 more
Mar 9, 2022

Uveal Melanoma Trial in Pittsburgh (Tebentafusp)

Not yet recruiting
  • Uveal Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Oct 5, 2023

AML, MDS, ALL, Adult Trial in Hackensack, New York (SOC + TSC-100, SOC + TSC-101, Control)

Recruiting
  • AML
  • +2 more
  • SOC + TSC-100
  • +2 more
  • Hackensack, New Jersey
  • +1 more
Aug 11, 2022

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma Trial in Seattle (Allogeneic Hematopoietic

Recruiting
  • Acute Lymphoblastic Leukemia
  • +16 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 1, 2022

Hepatocellular Cancer, AFP Expressing Tumors Trial in Worldwide (Autologous genetically modified AFP?³³²T cells)

Active, not recruiting
  • Hepatocellular Cancer
  • AFP Expressing Tumors
  • Autologous genetically modified AFPᶜ³³²T cells
  • Phoenix, Arizona
  • +20 more
Aug 26, 2022

HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma Trial in Houston

Active, not recruiting
  • HLA-A*0201 Positive Cells Present
  • +3 more
  • Aldesleukin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 25, 2022

Select Advanced Solid Tumors Trial in Spain, United Kingdom, United States (IMC-C103C)

Recruiting
  • Select Advanced Solid Tumors
  • Los Angeles, California
  • +18 more
Mar 10, 2022

Acute Myeloid Leukemia, EBV-Positive Neoplastic Cells Present, HLA-A*0201 Positive Cells Present Trial in Seattle (Aldesleukin,

Terminated
Has Results
  • Acute Myeloid Leukemia
  • +4 more
  • Aldesleukin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 15, 2021

Urinary Bladder Cancer, Melanoma, Head Neck Cancer Trial in Canada, United States (Autologous genetically modified MAGE-A4?¹º³²T

Active, not recruiting
  • Urinary Bladder Cancer
  • +9 more
  • Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
  • Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
  • Miami, Florida
  • +10 more
Aug 9, 2022

Colorectal Cancer, Gastric Cancer, Pancreatic Cancer Trial in Huntersville, Canton (CUE-102)

Recruiting
  • Colorectal Cancer
  • +3 more
  • Huntersville, North Carolina
  • +1 more
Jul 5, 2022

Esophageal Cancer, Esophagogastric Junction Cancer Trial in Worldwide (Autologous genetically modified ADP-A2M4CD8 cells)

Recruiting
  • Esophageal Cancer
  • Esophagogastric Junction Cancer
  • Autologous genetically modified ADP-A2M4CD8 cells
  • Duarte, California
  • +33 more
Aug 23, 2022

Advanced Solid Tumor Trial in Beijing (YK0901 cells)

Not yet recruiting
  • Advanced Solid Tumor
  • YK0901 cells
  • Beijing, China
    Department of GI Oncology, Peking University Cancer Hospital
Jun 27, 2023